ID | 32971 |
フルテキストURL | |
著者 |
Ito, Tatsuo
Science of Functional Recovery and Reconstruction, Graduate School of Medicine and Dentistry, Okayama University
Ouchida, Mamoru
Department of Molecular Genetics, Graduate School of Medicine and Dentistry, Okayama University
Kaken ID
publons
researchmap
Morimoto, Yuki
Science of Functional Recovery and Reconstruction, Graduate School of Medicine and Dentistry, Okayama University
Yoshida, Aki
Science of Functional Recovery and Reconstruction, Graduate School of Medicine and Dentistry, Okayama University
Jitsumori, Yoshimi
Department of Molecular Genetics, Graduate School of Medicine and Dentistry, Okayama University
Ozaki, Toshifumi
Science of Functional Recovery and Reconstruction, Graduate School of Medicine and Dentistry, Okayama University
Kaken ID
publons
researchmap
Sonobe, Hiroshi
Department of Laboratory Medicine and Pathology, National Fukuyama Hospital
Inoue, Hajime
Science of Functional Recovery and Reconstruction, Graduate School of Medicine and Dentistry, Okayama University
Shimizu, Kenji
Department of Molecular Genetics, Graduate School of Medicine and Dentistry, Okayama University
Kaken ID
publons
researchmap
|
抄録 | About 97% of synovial sarcomas harbor the SYT-SSX fusion gene by chromosomal
translocation. We found that the histone deacetylase (HDAC) inhibitor FK228
significantly suppressed the growth of synovial sarcoma cells as compared with that of
osteosarcoma. The 50% growth inhibition IC50 value we obtained for FK228 was 0.02-0.2 nM, and it indicates that its suppression effect on synovial sarcoma cells is the highest of any of the HDAC inhibitors yet reported. It was not likely that the growth suppression of FK228 depends on the doubling time of these cells. Introduction of SYT-SSX cDNA into HEK293 cells enhanced the sensitivity of the cells for FK228.
Immunostaining of the FK228-treated cells using an anti-acetyl-histone H3 antibody showed that FK228 inhibits deacetylation of histone. In a mice assay, the growth of synovial sarcoma cells was markedly inhibited by FK228 treatment, and the invasion of tumors into surrounding tissues was suppressed. These results suggest that FK228 may be useful in developing therapeutic strategies to treat synovial sarcoma.
|
キーワード | histone deacetylase inhibitor
synovial sarcoma
growth inhibition
in vivo
|
備考 | Digital Object Identifer:10.1016/j.canlet.2004.10.030
Published with permission from the copyright holder. This is the author's copy, as published in Cancer Letters, June 2005, Volume 224, Issue 2, Pages 311-319. Publisher URL:http://dx.doi.org/10.1016/j.canlet.2004.10.030 Direct access to Thomson Web of Science record Copyright © 2004 Elsevier Ireland Ltd. All rights reserved. |
発行日 | 2005-06-28
|
出版物タイトル |
Cancer Letters
|
巻 | 224巻
|
号 | 2号
|
出版者 | Elsevier Ireland Ltd.
|
開始ページ | 311
|
終了ページ | 319
|
ISSN | 0304-3835
|
NCID | AA00598513
|
資料タイプ |
学術雑誌論文
|
言語 |
英語
|
著作権者 | Elsevier Ireland Ltd.
|
論文のバージョン | author
|
査読 |
有り
|
DOI | |
PubMed ID | |
Web of Science KeyUT | |
Submission Path | biology_general/28
|